S&P 500 Giants Soars 20% On $26 Billion Deal For Geothermal, Natural Gas Giant Calpine
Constellation Energy jumped Friday after announcing that it will buy Calpine, adding geothermal and more natural gas to its ...
Vir Biotechnology: Buy Rating Supported by Promising TCE Programs and Strategic Partnerships
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...
Hosted on MSN9h
Morgan Stanley Upgrades Vir Biotechnology (VIR)
Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal ...
Vietnam Investment Reviev11h
Singapore's August Global Partners invests in Gene Solutions
August Global Partners will assist Gene Solutions in enhancing the performance of their oncology solutions by providing ...
IGM Biosciences (IGMS) was downgraded to a Sell Rating at Morgan Stanley
IGM Biosciences (IGMS – Research Report) received a Sell rating and a $2.00 price target from Morgan Stanley analyst Michael Ulz today. The ...
Wall Street Journal16h
Vir Biotechnology Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58%
Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...
Vir Biotech upgraded at Morgan Stanley on cancer drug data
Morgan Stanley upgraded Vir Biotechnology (NASDAQ:VIR) to Overweight from Equal Weight on Thursday after the cancer drug ...
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.